Rice Hall James & Associates LLC Cuts Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Rice Hall James & Associates LLC lessened its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 63.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 418,036 shares of the biotechnology company's stock after selling 739,219 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.18% of ADMA Biologics worth $8,357,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Quest Partners LLC bought a new position in shares of ADMA Biologics during the second quarter valued at $29,000. EntryPoint Capital LLC bought a new position in ADMA Biologics during the 1st quarter worth $31,000. USA Financial Formulas lifted its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after buying an additional 539 shares during the period. CWM LLC lifted its holdings in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after buying an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $93,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ADMA. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $15.50.

ADMA Biologics Trading Up 18.8 %

NASDAQ ADMA traded up $3.06 during trading hours on Friday, hitting $19.37. 11,734,453 shares of the company's stock were exchanged, compared to its average volume of 3,631,981. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of 142.64 and a beta of 0.62. The stock has a 50-day simple moving average of $17.83 and a 200 day simple moving average of $13.27. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a 1-year low of $3.40 and a 1-year high of $21.13.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company's quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.02) EPS. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.